Why is research in early-stage cancer research so low?

Vinay Prasad, Stephan Lindner

Research output: Contribution to journalArticle

Abstract

According to Budish, Roin and Williams (2015), drug development for early-stage cancer drugs is low because of missing financial incentives, and surrogates can overcome this distortion. We argue that technological barriers can also explain such low drug development. We first summarize medical literature describing these barriers and then augment their data to simultaneously assess the role of incentives versus barriers. Our results suggest that technological barriers suppress research in early-stage solid cancer and that surrogates may at best moderately increase drug development for such cancers.

Original languageEnglish (US)
Pages (from-to)4-8
Number of pages5
JournalJournal of Cancer Policy
Volume17
DOIs
StatePublished - Sep 1 2018

Fingerprint

Research
Pharmaceutical Preparations
Motivation
Neoplasms

Keywords

  • Cancer
  • Drug development
  • Surrogates

ASJC Scopus subject areas

  • Oncology
  • Health Policy

Cite this

Why is research in early-stage cancer research so low? / Prasad, Vinay; Lindner, Stephan.

In: Journal of Cancer Policy, Vol. 17, 01.09.2018, p. 4-8.

Research output: Contribution to journalArticle

@article{af64d62dde274f179310b91a77b41488,
title = "Why is research in early-stage cancer research so low?",
abstract = "According to Budish, Roin and Williams (2015), drug development for early-stage cancer drugs is low because of missing financial incentives, and surrogates can overcome this distortion. We argue that technological barriers can also explain such low drug development. We first summarize medical literature describing these barriers and then augment their data to simultaneously assess the role of incentives versus barriers. Our results suggest that technological barriers suppress research in early-stage solid cancer and that surrogates may at best moderately increase drug development for such cancers.",
keywords = "Cancer, Drug development, Surrogates",
author = "Vinay Prasad and Stephan Lindner",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.jcpo.2018.07.003",
language = "English (US)",
volume = "17",
pages = "4--8",
journal = "Journal of Cancer Policy",
issn = "2213-5383",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Why is research in early-stage cancer research so low?

AU - Prasad, Vinay

AU - Lindner, Stephan

PY - 2018/9/1

Y1 - 2018/9/1

N2 - According to Budish, Roin and Williams (2015), drug development for early-stage cancer drugs is low because of missing financial incentives, and surrogates can overcome this distortion. We argue that technological barriers can also explain such low drug development. We first summarize medical literature describing these barriers and then augment their data to simultaneously assess the role of incentives versus barriers. Our results suggest that technological barriers suppress research in early-stage solid cancer and that surrogates may at best moderately increase drug development for such cancers.

AB - According to Budish, Roin and Williams (2015), drug development for early-stage cancer drugs is low because of missing financial incentives, and surrogates can overcome this distortion. We argue that technological barriers can also explain such low drug development. We first summarize medical literature describing these barriers and then augment their data to simultaneously assess the role of incentives versus barriers. Our results suggest that technological barriers suppress research in early-stage solid cancer and that surrogates may at best moderately increase drug development for such cancers.

KW - Cancer

KW - Drug development

KW - Surrogates

UR - http://www.scopus.com/inward/record.url?scp=85051263112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051263112&partnerID=8YFLogxK

U2 - 10.1016/j.jcpo.2018.07.003

DO - 10.1016/j.jcpo.2018.07.003

M3 - Article

VL - 17

SP - 4

EP - 8

JO - Journal of Cancer Policy

JF - Journal of Cancer Policy

SN - 2213-5383

ER -